AJANTPHARM / Q4-FY26 / risks

Keep the risk register visible.

Ajanta Pharma · Material risks, their source context, and severity in the latest available quarter.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ4-FY26 · 2026-05-15Back to quarter ↗

Risk intelligence

Material risks this quarter

Middle East conflict impact on costs

Prolonged conflict could increase raw material and freight costs, which management expects to absorb for 2-3 months but may pressure margins beyond.

high

US FDA Form 483 at Paithan facility

Five observations received; potential escalation could impact US filings or existing product supplies if not resolved satisfactorily.

medium

Asia business recovery uncertainty

Asia declined 10% in Q4 due to logistics disruptions; while management expects high double-digit growth, demand normalization is unproven.

medium

Promoter pledge increase

Pledge by two promoter brothers for unrelated businesses has risen; though management says it's not company-related, it could signal personal financial stress.

low